Lymphoproliferative syndrome

This study tests whether a stem cell transplant can cure people with serious immune system disorders. Participants, aged 4 to 69, receive healthy donor stem cells to rebuild their immune system. The goal is to see if the transplant can permanently fix the immune defect and elimin…

This study tests whether a stem cell transplant from a healthy donor can help people with severe primary immunodeficiencies. Participants aged 4 to 75 receive chemotherapy before the transplant to prepare their body. The goal is to see if the procedure is safe and can improve imm…

This phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…

This phase 3 trial tests tabelecleucel, a cell therapy made from donor immune cells, in 115 organ or stem cell transplant patients who developed a rare cancer (EBV+ PTLD) after standard treatment failed. The goal is to see if it can shrink tumors and improve outcomes. Participant…

This early-stage trial tests a new gene therapy called KLN-1010 for people with multiple myeloma that has come back or stopped responding to treatment. Instead of removing cells and engineering them in a lab, this therapy works inside the body to create special immune cells that …

This study tests a lab-made human protein called CYT107 in 55 people with HIV and Kaposi sarcoma. The protein aims to boost T cells, which may help shrink cancer tumors. Participants receive weekly injections for up to 4 weeks, with follow-up for 3 years.

This study tests a drug called pacritinib in people with HIV who have two rare conditions caused by the Kaposi sarcoma herpesvirus (KSHV): KSHV-associated multicentric Castleman disease (MCD) and KSHV inflammatory cytokine syndrome (KICS). These conditions cause severe, life-thre…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

The DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…

This study tests whether a blood test (ctDNA) can help doctors choose the right treatment for people with a type of lymphoma that happens after an organ transplant (PTLD). About 30 participants will be split into low-risk and high-risk groups. Low-risk patients will get only the …

This study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with ibrutinib, in adults with relapsed or refractory primary central nervous system lymphoma (PCNSL). The trial has multiple parts to find the safest dose and see if the drug shrinks tumors. …

This study tests a drug called AVM0703, a very strong steroid, given as a one-time IV infusion. It aims to see if it is safe and can shrink tumors in people with certain blood cancers like lymphoma and leukemia. The trial will enroll 144 participants aged 12 and older.

This phase 2 trial is testing whether epcoritamab, a type of antibody, can help people with Waldenstrom Macroglobulinemia (a rare blood cancer) who have already received treatment. The study will enroll 20 participants and measure how many respond to the drug. Epcoritamab is give…

This study tests a new way to make immune cells (called GRALE T cells) that are trained to attack cells infected with the Epstein-Barr virus (EBV), which is linked to some lymphomas. The trial includes people with Hodgkin or non-Hodgkin lymphoma, or related diseases, whose cancer…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated follicular lymphoma or other slow-growing non-Hodgkin lymphomas. The goal is to see if this drug pair can shrink tumors and control the disease. About 49 participant…

This study tests a drug called pacritinib in 100 people with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. Participants take the drug and are monitored with scans and skin asse…

This study tests whether the drug pacritinib is safe and effective for adults with Waldenström macroglobulinemia, a rare blood cancer, when previous treatments have stopped working. About 30 participants will receive pacritinib and be monitored for tumor shrinkage and side effect…

This trial tests the drug entrectinib (Rozlytrek) in people with rare cancers that have a specific genetic change called ROS1 fusion. The drug is already approved for some lung cancers, but researchers want to see if it works for other tumor types. About 30 adults, teens, and chi…

This trial tests atezolizumab, a drug already approved for several cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 wee…

This study tests a drug called alectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change called ALK. About 30 adults, teens, and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops…

This study tests an experimental therapy that uses special immune cells (T-cells) from a donor to fight cytomegalovirus (CMV) infection in people who have had a stem cell transplant. The therapy aims to boost the patient's immune system to clear the infection. About 20 participan…

This study tests an 8-week virtual rehab program (CaRE@Home) for adults who finished cancer treatment for breast, colorectal, head and neck cancers, or lymphoma within the last two years. The goal is to see if the program reduces disability and improves physical function, anxiety…

This study follows people with autoimmune lymphoproliferative syndrome (ALPS) and their relatives over many years. Researchers will collect blood and tissue samples, track symptoms, and study genetics to better understand why the immune system attacks the body. The goal is to lea…

This study is a large registry that collects health information and leftover tumor or blood samples from up to 75,000 children and young adults with cancer. The goal is to track outcomes and gather data to help doctors find better ways to treat and care for these patients over ti…

This study looks at gene changes that might cause low blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas after CAR-T therapy. About one-third of patients have low blood counts lasting more than 30 days after treatment. Researchers will test blood a…

This study aims to find genetic mutations that cause chronic active Epstein-Barr virus (CAEBV), a rare and serious disease mainly affecting children and young adults. Researchers will analyze blood and tissue samples from up to 50 patients and 150 relatives, plus anonymous donor …

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study collects tumor samples and medical information from people with lymphoma or related blood cancers who have a family history of these diseases. Researchers want to find genetic changes that may increase the risk of developing lymphoma. Participants provide blood or tiss…

This study is a large registry that will follow 9,000 adults with lymphoproliferative disorders (a type of blood cancer) for up to 10 years. Researchers aim to learn how long people live, how different treatments work, and what factors affect the disease. No new treatments are gi…

This study collects and analyzes genetic and molecular data from 250 people with various blood cancers, including leukemia and lymphoma. Researchers will test cancer cells in the lab with many drugs to see which ones work best. The goal is to match genetic features with drug resp…

This study is collecting bone marrow, blood, and tissue samples from over 1,000 people with various blood cancers. Researchers will use advanced genetic and protein analysis to identify unique markers for each cancer type. They will also test cancer cells against a library of 300…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…